CVS Health (NYSE:CVS) Lowered to “Hold” Rating by Wall Street Zen

CVS Health (NYSE:CVS) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Wednesday.

CVS has been the topic of several other reports. TD Cowen boosted their target price on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Barclays raised their price objective on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Royal Bank Of Canada boosted their price objective on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. UBS Group increased their target price on shares of CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, Argus upped their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Twenty-one research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.04.

CVS Health Stock Performance

NYSE CVS opened at $106.11 on Wednesday. The stock has a market capitalization of $135.39 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 1.04 and a beta of 0.61. The business’s 50 day moving average is $97.87 and its two-hundred day moving average is $84.60. CVS Health has a 12-month low of $58.50 and a 12-month high of $106.93. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the business earned $2.25 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts expect that CVS Health will post 7.44 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On CVS Health

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares during the period. State Street Corp increased its holdings in shares of CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Capital International Investors raised its position in shares of CVS Health by 3.4% in the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after buying an additional 900,153 shares during the period. Norges Bank acquired a new position in CVS Health in the fourth quarter valued at $1,666,265,000. Finally, Morgan Stanley grew its position in CVS Health by 6.3% during the fourth quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after acquiring an additional 1,211,631 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised CVS Health’s price target to $118 from $108 and kept a buy rating, signaling more upside from current levels.
• Positive Sentiment: CVS Caremark announced an agreement with the FTC that it says will improve transparency and affordability in prescription drug pricing, which may help reduce regulatory overhang and support investor confidence. Article Title
• Positive Sentiment: Management also highlighted GLP-1 support expansion across CVS pharmacies, MinuteClinic, and virtual channels, which could strengthen its healthcare services offering and drive more consumer traffic. Article Title
• Neutral Sentiment: Commentary from Jim Cramer and several value-oriented articles reinforced the view that CVS remains a popular large-cap healthcare stock, but these pieces are more sentiment-driven than fundamentally new.
• Negative Sentiment: The FTC settlement also underscores continued scrutiny of CVS Caremark’s rebate and pricing practices, including changes to how it handles drug rebates and future TrumpRx deductible credits, which could pressure margins or business terms over time. Article Title

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.